Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Avidea Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avidea Technologies Utilizes GenScript\\'s Synthesized Neoantigen Peptides for Novel Personalized Cancer Vaccine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Avidea Technologies","sponsor":"Barinthus Biotherapeutics","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"$12.5 million","newsHeadline":"Vaccitech Acquires Avidea Technologies to Expand Product Pipeline and Strengthen Scientific Leadership in Immunotherapies and Vaccines","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"}]

    Find Clinical Drug Pipeline Developments & Deals by Avidea Technologies

    Menu

    Avidea Technologies

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Avidea Technologies

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Vaccitech Acquires Avidea Technologies to Expand Product Pipeline and Strengthen Scientific Leadership in Immunotherapies and Vaccines

              Details:

              The acquisition of Avidea strengthens Vaccitech’s position as a leader in immunotherapies and vaccines including SNAPvax CV, using the SNAPvaxTM platform uses self-assembly to co-deliver multiple antigens and immunomodulators in nanoparticles of precise size and composition.

              Lead Product(s): SNAPvax Cancer Vaccine

              Therapeutic Area: Oncology Product Name: SNAPvax CV

              Highest Development Status: IND Enabling Product Type: Vaccine

              Partner/Sponsor/Collaborator: Barinthus Biotherapeutics

              Deal Size: $40.0 million Upfront Cash: $12.5 million

              Deal Type: Acquisition December 13, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Avidea Technologies

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Avidea Technologies Utilizes GenScript's Synthesized Neoantigen Peptides for Novel Personalized Cancer Vaccine

              Details:

              The groundbreaking peptide-based personalized cancer vaccine was shown to more efficiently induce T-cell responses against tumor neoantigens compared to traditional vaccines.

              Lead Product(s): SNP-7/8a

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 15, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY